In multiple animal models of respiratory diseases, the treatment with XC221GI led to controlling the levels of CXCL9, CXCL10, CXCL11, IL-6 and IL-8, and to decrease of extent of the pathogen-driven cytokine storm. Here, CXCL10 is linked to respiratory system disorder.